Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD)

Matthew Chan, Lauren Haydu, Alexander M. Menzies, Mary W. F. Azer, Oliver Klein, Alexander Guminski, Richard Kefford, Georgina Long

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)9062-9062
Number of pages1
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2013
EventAnnual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States
Duration: 31 May 20134 Jun 2013

Cite this